Pharmaceutical Contract Development and Manufacturing Market to Reach US$ 428.50 Billion by 2033 at 9.5% CAGR; North America Leads with 38% Share | Key Players Lonza, Thermo Fisher, Catalent

The pharmaceutical contract development and manufacturing market reached US$ 198.92 billion in 2024 and is expected to reach US$ 428.50 billion by 2033, growing at a CAGR of 9.5% during the forecast period 2025-2033. Market growth is driven by increasing outsourcing of drug development and manufacturing activities by pharmaceutical and biotechnology companies to reduce costs, accelerate time-to-market, and access specialized capabilities. Rising demand for biologics, personalized medicines, and complex drug formulations is further expanding the need for contract development and manufacturing organizations (CDMOs) with advanced technical expertise.

North America held the largest market share due to a strong pharmaceutical and biotech presence, high R&D expenditure, and early adoption of outsourcing strategies. Europe followed with a well-established CDMO landscape and supportive regulatory framework for contract manufacturing. Asia-Pacific is expected to witness the fastest growth, driven by cost advantages, expanding manufacturing infrastructure, increasing contract service capabilities, and growing participation of regional players in global pharmaceutical supply chains.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/pharmaceutical-contract-development-and-manufacturing-market?sai-v

The pharmaceutical contract development and manufacturing market refers to the global industry focused on outsourced services for drug development, formulation, and large-scale pharmaceutical manufacturing.

Key Developments
✅ January 2026: In North America, contract development and manufacturing organizations (CDMOs) expanded capacity for biologics, cell and gene therapies, and advanced modalities, driven by investments from Thermo Fisher Scientific, Catalent, and Lonza to support increased outsourcing by innovator pharma companies.

✅ January 2026: In Europe, demand for integrated end-to-end CDMO services covering early discovery, analytical development, and commercial manufacturing grew, with key contributions from Recipharm, Boehringer Ingelheim BioXcellence, and Wacker Biotech enhancing service breadth and regulatory support.

✅ December 2025: In Asia-Pacific, expansion of GMP-compliant facilities and regional manufacturing hubs accelerated to support local and global supply chains, led by WuXi AppTec, Samsung Biologics, and AGC Biologics scaling biologics and small molecule production.

✅ December 2025: Globally, technological advancements in continuous manufacturing and single-use bioprocessing improved efficiency, reduced changeover times, and enhanced flexibility across CDMO platforms, with innovation from Sartorius, Eppendorf, and Danaher (Pall/Applikon).

✅ November 2025: In Latin America, partnerships between multinational CDMOs and local partners expanded fill-finish and secondary packaging services to improve regional supply resilience, involving Eurofins Scientific, Catalent, and Thermo Fisher Scientific.

✅ October 2025: Worldwide, the adoption of advanced analytics, PAT (process analytical technology), and digital twin process modeling enhanced quality and scale-up predictability, with platforms developed by Siemens, Emerson, and ABB improving process control.

Mergers & Acquisitions
✅ January 2026: In the United States, Thermo Fisher Scientific completed the acquisition of a specialized biologics CDMO to broaden its contract development and manufacturing service offerings across advanced therapy modalities.

✅ December 2025: In Europe, Recipharm acquired a regional small molecule and sterile manufacturing facility to strengthen its end-to-end CDMO footprint and support expanding commercialization demand.

✅ November 2025: In Asia-Pacific, WuXi AppTec acquired a contract manufacturing operation focused on high-value active ingredients and biologics to enhance its integrated service portfolio.

Key Players
Lonza Group | Thermo Fisher Scientific Inc. | Catalent | Recipharm AB | AbbVie | Siegfried Holding AG | Evonik Industries | Boehringer Ingelheim | Piramal Pharma Limited | Fujifilm Healthcare | Asymchem Laboratories (Tianjin) Co., Ltd. | WuXi AppTec | Others

Key Highlights
Lonza Group holds 18% share, driven by its leadership in contract development and manufacturing services (CDMO), strong biologics capabilities, and long-term partnerships with global pharmaceutical companies.

Thermo Fisher Scientific Inc. holds 16% share, supported by its integrated CDMO services, extensive manufacturing infrastructure, and strong presence across small molecules, biologics, and advanced therapies.

Catalent holds 14% share, leveraging expertise in drug delivery technologies, oral and injectable manufacturing, and strong customer base in branded and specialty pharmaceuticals.

WuXi AppTec holds 13% share, driven by its end-to-end CRDMO model, strong footprint in Asia-Pacific, and rapid expansion in biologics and cell and gene therapy services.

Recipharm AB holds 9% share, supported by diversified dosage-form manufacturing, strong European presence, and focus on complex generics and specialty drugs.

Boehringer Ingelheim holds 8% share, leveraging biologics manufacturing expertise, high-quality standards, and long-standing relationships with innovator companies.

Evonik Industries holds 7% share, driven by its strength in pharmaceutical excipients, drug delivery systems, and specialized active ingredient manufacturing.

Siegfried Holding AG holds 6% share, supported by strong small-molecule API manufacturing, regulatory compliance, and customer-centric CDMO services.

Piramal Pharma Limited holds 5% share, leveraging cost-efficient manufacturing, expanding global CDMO footprint, and capabilities in complex APIs and formulations.

Fujifilm Healthcare holds 3% share, driven by investments in biopharmaceutical manufacturing platforms and advanced cell culture technologies.

Asymchem Laboratories (Tianjin) Co., Ltd. holds 2% share, supported by custom synthesis expertise and growing international client base.

Others collectively hold 0-5% share, comprising regional CDMOs and niche service providers expanding capabilities in specialty pharmaceutical manufacturing.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=pharmaceutical-contract-development-and-manufacturing-market?sai-v

Market Drivers
- Increasing outsourcing of drug development and manufacturing activities by pharmaceutical and biotechnology companies to reduce costs and accelerate time-to-market.

- Growing demand for contract development and manufacturing organization (CDMO) services driven by expansion of biologics, complex therapies, and personalized medicines.

- Rising focus on core competencies by pharmaceutical firms leading to partnerships for formulation development, scale-up, and commercial manufacturing.

- Advancements in manufacturing technologies including continuous processing, single-use systems, and high-potency API production enhancing CDMO capabilities.

- Supportive regulatory frameworks and quality standards promoting compliance and global outsourcing adoption.

Industry Developments
- Expansion of end-to-end service offerings by CDMOs covering early discovery, formulation, analytical testing, and commercial manufacturing.

- Strategic mergers, acquisitions, and alliances to enhance global footprint, capacity, and specialized service portfolios.

- Growth of biologics and cell & gene therapy manufacturing capabilities with advanced containment and quality systems.

- Increasing investments in flexible and modular facilities to support multi-product production and rapid capacity scaling.

- Integration of digital solutions, automation, and advanced analytics to optimize process efficiency, traceability, and compliance.

Regional Insights
North America - 38% share: "Driven by strong biopharmaceutical R&D ecosystem, high outsourcing adoption, advanced manufacturing infrastructure, and presence of leading CDMO providers."

Europe - 27% share: "Supported by established pharmaceutical manufacturing base, regulatory expertise, and growing demand for specialized CDMO services."

Asia Pacific - 25% share: "Fueled by cost-effective manufacturing hubs, expanding biotech sector, rising contract services adoption, and supportive government initiatives."

Latin America - 6% share: "Driven by emerging pharmaceutical manufacturing activities and increasing interest in outsourced development and manufacturing solutions."

Middle East & Africa - 4% share: "Supported by improving healthcare infrastructure, growing pharmaceutical production, and rising investments in contract manufacturing capabilities."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/pharmaceutical-contract-development-and-manufacturing-market?sai-v

Key Segments

By Service
Pharmaceutical manufacturing services hold a major share, driven by increasing outsourcing of production to optimize costs, ensure regulatory compliance, and scale manufacturing capacity. Drug development services are witnessing strong growth as companies seek external expertise for preclinical research, clinical trial support, and formulation development to accelerate time-to-market. Biologics manufacturing services are expanding rapidly, supported by rising demand for monoclonal antibodies, vaccines, and cell- and gene-based therapies requiring specialized manufacturing capabilities.

By End-User
Large pharmaceutical companies dominate the market, leveraging outsourcing to enhance flexibility and manage complex global supply chains. Small and mid-sized pharmaceutical companies represent a fast-growing segment, relying on service providers to access advanced technologies and reduce capital investment. Generic pharmaceutical companies maintain steady demand for cost-efficient manufacturing and development services to support high-volume production. Other end users include biotechnology firms, virtual pharma companies, and research-driven startups.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.